论文部分内容阅读
溃疡性结肠炎(ulcerative colitis,UC)是一种常见的慢性、反复发作的肠疾病,该病病因不明,一直缺乏满意的治疗药物。近年来,随着对UC病因的深入了解和新型药物的开发,许多新型制剂开始用于临床。采用能在回肠或结肠末端释放美沙拉秦(mesalazine,5-ASA)的制剂,治疗、维持及缓解溃疡性结肠炎已经取得良好疗效,且不良反应少见。本文对目前临床上常用的几种5-ASA剂型进行简介,并重点对治疗溃疡性结肠炎的新药-APRISO的制剂特点、药代动力学、临床评价、不良反应及其药物相互作用等加以综述。
Ulcerative colitis (UC) is a common, chronic, recurrent bowel disease whose cause is unknown and has been lacking in satisfactory therapeutic drugs. In recent years, with the in-depth understanding of the etiology of UC and the development of new drugs, many new agents have started to be used clinically. With formulations that release mesalazine (5-ASA) at the distal ileum or colon, good results have been achieved with the treatment, maintenance and relief of ulcerative colitis with rare adverse reactions. In this paper, several 5-ASA dosage forms commonly used in clinic are introduced briefly, and the preparation characteristics, pharmacokinetics, clinical evaluation, adverse reactions and their drug interactions of APRISO, which is a new drug for treating ulcerative colitis, are reviewed .